Braveheart Bio, Inc.

BRVE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$21.51

+$0.32 · +1.51%

Oct 30, 4:00 PM ET

Latest quote

$21.51

+$0.32 · +1.51%

Regular session · ET · Market data may be delayed.

Company profile

Company website

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Travis Murdoch
Listed since: Aug 6, 2026
Employees: 49

Market position

Day range

Current $21.51

$20.745$21.77

52-week range

Current $21.51

$17.86$32.00

Open: $21.29
Previous close: $21.19
Volume: 533.67K; 1.11× average
Average volume: 480.92K; Average daily volume
Market cap: 1.52B USD
Beta: 0; Market reference 1
50-day average: $23.518; -8.54% below average
200-day average: $24.2326; -11.24% below average

Earnings

EPS beat rate: 0%; 0 beats, 1 miss, 0 met estimates
Average EPS surprise: -193.31%; 1 comparable report
Latest EPS result: -2.51; Estimate 2.69 · Miss by 193.31%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$45.25

110.37% upside

Past 12 months12-month forecastHigh $48.00Average $45.25Low $40.00

Recent analyst actions

1 institution

Cantor FitzgeraldmaintainOverweightOct 20, 2026

BRVE news

globenewswire.comOct 30, 2026

Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

Read source

globenewswire.comOct 30, 2026

Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

Read source

seekingalpha.comOct 20, 2026

Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting operations into 2029…

Read source

defenseworld.netOct 2, 2026

Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened

Shares of Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) were down 7.3% during mid-day trading on Wednesday. The stock traded as low as $20.86 and last traded at $20.7090. 36,478 shares were traded during mid-day…

Read source

globenewswire.comSep 16, 2026

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

Read source

globenewswire.comSep 8, 2026

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart…

Read source